Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Lowered to $3.00 at B. Riley

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price objective reduced by B. Riley from $4.00 to $3.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the stock. B. Riley also issued estimates for Lineage Cell Therapeutics’ Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2027 earnings at ($0.08) EPS.

Several other research firms have also weighed in on LCTX. Maxim Group dropped their price objective on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. D. Boral Capital reiterated a “buy” rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Finally, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $4.20.

Lineage Cell Therapeutics Price Performance

Shares of NYSEAMERICAN LCTX opened at $0.52 on Friday. The business’s 50-day simple moving average is $0.60. The firm has a market cap of $114.62 million, a price-to-earnings ratio of -4.33 and a beta of 1.21. Lineage Cell Therapeutics has a one year low of $0.48 and a one year high of $1.61.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several institutional investors have recently bought and sold shares of LCTX. Fort Sheridan Advisors LLC lifted its stake in shares of Lineage Cell Therapeutics by 71.5% in the fourth quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock worth $28,000 after buying an additional 23,000 shares during the last quarter. Atria Wealth Solutions Inc. acquired a new position in Lineage Cell Therapeutics during the 4th quarter worth $29,000. HighTower Advisors LLC boosted its holdings in Lineage Cell Therapeutics by 49.5% during the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock valued at $29,000 after acquiring an additional 19,100 shares during the period. SG Americas Securities LLC increased its stake in shares of Lineage Cell Therapeutics by 35.5% in the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock worth $35,000 after purchasing an additional 18,053 shares during the period. Finally, Two Sigma Advisers LP lifted its position in shares of Lineage Cell Therapeutics by 312.2% during the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock worth $44,000 after purchasing an additional 65,864 shares during the last quarter. 62.47% of the stock is currently owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.